Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 in Advanced Pulmonary Neuroendocrine Tumor
NCT01175096Phase 2Unknown
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jul 2010
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in pulmonary neuroendocrine tumor, sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Safety and tolerability at 28 days. Status: unknown.
02
Drugs
everolimus
03
Conditions
pulmonary neuroendocrine tumor
Beyond the preview
Go deeper on NCT01175096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01175096.